View PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.

PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.

This programme, (supported by CEPI funding), will provide the infrastructure to help design and select the lead antigen through proof-of-concept preclinical studies, progressing to initial clinical development through Phase I/II studies. DIOSynVax aim to establish clinical proof of concept for a novel vaccine candidate with the potential to provide broad protection against Sarbecovirus, Merbecovirus, Embecovirus and Nobecovirus.

Read More

View Adopting a New Agile Approach to CRO Clinical Trial Management

Adopting a New Agile Approach to CRO Clinical Trial Management

Following its reputation of excellence in delivering investigator-led studies, PHARMExcel was selected to manage the Covid-19 vaccine booster study.

Read More

View New EU Clinical Trial Regulation

New EU Clinical Trial Regulation

The new EU clinical trial regulation (CTR) is set to revolutionise clinical trial processes across Europe impacting all European Member states and organisations wanting to run clinical trials across these regions. How can organisations prepare for the change and set themselves up successfully with a new CTR programme?

Read More

View Yvanne Enever, Founder/CEO reflects on 2021

Yvanne Enever, Founder/CEO reflects on 2021

We are pleased to say that 2021 has seen PHARMExcel busier than ever. From delivering the Worlds’ first Booster Vaccine clinical trial leading to the shaping of UK Government policy, to welcoming new, key staff appointments and undertaking several charity events for Macmillan Cancer Support, Team PHARMExcel showed dedication to the cause. As we complete…

Read More

View PHARMExcel delighted to be the selected U.K. CRO delivering this pivotal clinical trial alongside colleagues at University Southampton, Cambridge and DIOSynVax.

PHARMExcel delighted to be the selected U.K. CRO delivering this pivotal clinical trial alongside colleagues at University Southampton, Cambridge and DIOSynVax.

Read More

View PHARMExcel are pleased to announce the publication of the safety and immunogenicity data from the UK’s Covboost trial.

PHARMExcel are pleased to announce the publication of the safety and immunogenicity data from the UK’s Covboost trial.

Read More

View Covid booster jabs will begin to be offered across the UK from next week based on JCVI decisions following COVBoost clinical trial data.

Covid booster jabs will begin to be offered across the UK from next week based on JCVI decisions following COVBoost clinical trial data.

Read More

View PHARMExcel, a U.K. based CRO, is delighted to have been selected as the CRO to support the COVBoost study. Data has contributed to the MHRA approval decisions

PHARMExcel, a U.K. based CRO, is delighted to have been selected as the CRO to support the COVBoost study. Data has contributed to the MHRA approval decisions

Read More

View PHARMExcel supports recruitment of the first patient into INmuneBio’s pivotal MDS study showing promising results

PHARMExcel supports recruitment of the first patient into INmuneBio’s pivotal MDS study showing promising results

Read More

  1. Pages:
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. 6
  8. 7